Invest in the best stock opportunities right now and every-time.
Start Systematic Stock Investing ...in less than a minute.
Claris Lifesciences is currently trading at Rs. 180.25, up by 2.60 points or 1.46 % from its previous closing of Rs. 177.65 on the BSE.
The scrip opened at Rs. 179.50 and has touched a high and low of Rs. 182.35 and Rs. 179.50 respectively. So far 10239 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 232.00 on 03-Apr-2013 and a 52 week low of Rs. 142.05 on 18-Jun-2013.
Last one week high and low of the scrip stood at Rs. 184.90 and Rs. 175.05 respectively. The current market cap of the company is Rs. 1133.72 crore.
The promoters holding in the company stood at 60.21 % while Institutions and Non-Institutions held 26.28 % and 13.51 % respectively.
Claris Lifesciences has received the Abbreviated New Drug Application (ANDA) approval for Furosemide Injection in the United States of America (US). This product will be sold in 10 mg/ml formulation packed in 20mg/2ml, 40mg/4ml and 100mg/10ml single dose vials having approximately market size of $22 million. This brings the company’s total tally of approved and marketable ANDAs to 13 with estimated addressable market size of $204.33 million.
Furosemide is used to treat edema (fluid retention) that occurs with congestive heart failure and disorders of the liver, kidney, and lung. It is also used to control mild to moderate high blood pressure. It may be used in combination with other medications to treat more severe high blood pressure.
The product has been facing supply issues in USA during the past year on various occasions and has also featured in the USFDA shortage list since June 2012. Presently there are only 4 other companies who have an approved ANDA for this product. Claris is the only company out of the emerging markets to have received the ANDA approval for the US.
| Company Name | CMP |
|---|---|
| Redington | 216.95 |
| Adani Enterprises | 3263.50 |
| Amrapali Industries | 15.35 |
| Rashi Peripheral | 341.75 |
| Compuage Infocom | 3.71 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
